A clinical trial involving terlipressin was registered on November 6, 2026. The study, titled "Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)," is listed under identifier NCT07178366.
According to the registry record, the trial status is not yet recruiting. The phase is listed as not applicable. No enrollment has begun, and no outcomes or results have been reported at this stage.
The trial is designed to study acute-on-chronic liver failure, a condition in which terlipressin is an approved treatment option. As the study has not started recruiting, no information is yet available on participant numbers, methodology details beyond the title, or expected timelines for data collection.
This listing reflects only the current registration status as of the date shown. Any future updates to recruitment status, trial design, or results would appear as separate updates to the registry entry. Readers should note that a trial being registered does not indicate any outcome, safety finding, or efficacy signal for terlipressin.
For more background on terlipressin, including its approved uses, readers can consult the compound overview.